Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2024 Aug 15;19(8):e0308293. doi: 10.1371/journal.pone.0308293

Impact of blood meals taken on ivermectin-treated livestock on survival and egg production of the malaria vector Anopheles coluzzii under laboratory conditions

Sié Hermann Pooda 1,2,*, Domonbabele François de Salle Hien 3, Soumaïla Pagabeleguem 1,2, Andre Patrick Heinrich 4, Angélique Porciani 5, André Barembaye Sagna 5, Lamidi Zela 6, Lassane Percoma 2, Thierry Lefèvre 5, Roch Kounbobr Dabiré 3, Amnan Alphonsine Koffi 7, Rolf-Alexander Düring 4, Cédric Pennetier 5, Nicolas Moiroux 5, Karine Mouline 5,*
Editor: Pedro L Oliveira8
PMCID: PMC11326554  PMID: 39146278

Abstract

Treatment of livestock with endectocides such as ivermectin is viewed as a complementary vector control approach to address residual transmission of malaria. However, efficacy of this treatment may vary between animal species. Hence, our purpose was to investigate the effects of ivermectin treatments of common livestock species on life history traits of the opportunistic malaria vector Anopheles coluzzii. Sheep, goats and pigs were treated using injectable veterinary ivermectin formulation at the species-specific doses (recommended dose for all species and high dose in pig). Mosquito batches were exposed to treated and control (not injected) animals at different days after treatment. Daily mosquito mortality was recorded and fecundity assessed through the count of gravid females and the number of eggs they developed. The recommended dose of ivermectin induced a significant decrease in mosquito survival for up to 7 days after injection (DAI), with a decrease of 89.7%, 66.7%, and 48.4% in treated pigs, goats and sheep, respectively, compared to control animals. In treated pigs, the triple therapeutic dose decreased mosquito survival of 68.97% relatively to controls up to 14 DAI. The average number in gravid females Anopheles that survived after feeding on treated animals were reduced when blood-meals were taken on sheep (2.57% and 42.03% at 2 and 7 DAI), or on goats (decrease of the 28.28% and 73.64% respectively at 2 and 7 DAI). This study shows that ivermectin treatments to animals negatively impacts An. coluzzii life history traits and could reduce vector densities in areas where livestock live near humans. However, due to short-term efficacy of single dose treatments, repeated treatments and potentially increased dosages would be required to span the transmission season. The use of long-acting ivermectin formulations is discussed as a mean for extending efficacy while remaining cost effective.

Introduction

A remarkable reduction in the burden of malaria has been achieved globally over the past two decades. The incidence of the disease has declined from 82 per 1000 population at risk in 2000 to 57 in 2019. The malaria mortality rate has also decreased over the same period, from 30 per 100 000 population at risk to 15 per 100 000 in 2019 [1]. However, an increasing trend in malaria cases has been observed globally over the past 5 years. Malaria cases have increased from 218 million to 247 million between 2019 and 2021 [2], indicating that the current malaria prevention strategies are no longer adequate to control the disease and that new and/or complementary measures are urgently needed.

Indoor vector control tools such as LLINs and IRS have been critical in decreasing the burden of malaria by targeting anthropophilic (prefer to feed on humans), endophagic (prefer to bite indoors), and endophilic (prefer to rest indoors) malaria vectors [3]. Their wide-scale deployment has contributed to avoid approximatively 1.5 billion malaria cases between 2000 and 2019 [2]. However, these interventions have had limited impact on exophagic (prefer to bite outdoors), exophilic (prefer to rest outdoors) and zoophagic/opportunistic (blood feed on animals/do so occasionally when human are not available) malaria vectors such as An. arabiensis and An. coluzzii [4]. This could explain in part the high malaria transmission observed in many African countries where malaria vectors exhibit such characteristics, despite high coverage of LLINs and IRS [5].

Anopheles coluzzii, formerly An. gambiae M form, plays a significant role in malaria transmission in west Africa [6]. However, this highly anthropophilic species is increasingly reported to feed on non-human hosts (i.e. cattle, goats, dogs) [79]. This plastic feeding strategy of this yet highly innate anthropophagic species is thought to be the consequence of reduced accessibility of human hosts due to widescale deployment of LLINs and IRS, and the accessibility of close and readily accessible domestic animals hosts in agropastoral settings [79].

The main challenges with LLINs and IRS strategies are the persistence of residual transmission of Plasmodium due to mosquito populations resisting to insecticides (i.e. those that carry metabolic and target site mutations), or displaying behaviors that limit or avoid the contact with the molecules (i.e. Those that feed on livestock, bite and resting outdoors, display early or late aggressive behavior, exit early from houses to evade indoor insecticide exposure, etc.). Human host behaviors may also favor residual transmission through exposure to vectors (i.e. by staying or sleeping indoor or outdoor without protective measures). To target endophilic insecticide-resistant malaria vectors, new generations of LLINs (i.e. dual-active ingredients LLINs) were developed [10,11] and are now widely distributed to replace standard nets [12]. These tools will need, however, to be combined with complementary interventions that can target all vectors that are yet out of reach to achieve the malaria elimination goal. Hence, several interventions are currently under investigations, such as treating livestock with endectocides (i.e. ivermectin) [13], improving housing [14], the use of attractive toxic sugar baits [15], and larval source management [16].

In this context, studies have documented the efficacy of ivermectin in killing mosquitoes that took a blood meal on treated animals. The mosquitocidal effect has been demonstrated in major malaria vectors on cattle [1719], pigs [20] and dogs [21]. Small ruminants such as sheep and goats are not yet considered for this approach. These animals that usually live near human populations also represent an alternative blood source for malaria vectors that enables their reproduction and survival, hence sustaining their role in Plasmodium transmission and leaning toward zoopotentiation [22,23]. Therefore, using ivermectin for treating a large panel of peridomestic animals would represent an endectocide-based zooprophylactic approach, in the frame of the One-Health concept, which would virtuously intricate human’s and animal’s health [24].

Burkina Faso has shown similar malaria epidemiological trend than worldwide, owing to the intensive use of core interventions recommended by the World Health Organization (WHO) to fight the disease: chemoprevention (for pregnant women and children under 5 years), treatment of diagnosed cases with artemisinin-based combination therapies, and vector control (long-acting insecticide-treated mosquito nets, (LLINs), and indoor residual spraying (IRS) [25,26]. However, in areas where human live in close vicinity to domestic animals, which represent the largest, Soudano-Sahelian, part of the country, major malaria mosquitoes are zoophagic [7,27]); hence, targeting the animal component of malaria transmission using complementary approaches like endectocide treated livestock is there essential. According to Imbahale et al. [28], Burkina Faso is among the countries where such approach should be efficient at reducing malaria incidence.

The pharmacokinetics of ivermectin varies according to animal species, injected dose, and route of administration [29,30]. The systemic insecticidal effects of the drug on mosquitoes may then vary depending on the treated animal species, as it may also depend on the Anopheles vector species considered [31,32]. In the present study, a laboratory experiment was performed in Burkina Faso to investigate the effects of ivermectin on the survival and egg production of field derived An. coluzzii fed on treated local sheep, goats, and pigs. With the goal of proposing integrated vector control measures in a One health context, we focused on already used and proven veterinary practices by using at least the species-recommended therapeutic dose of the approved veterinary product, as applied to cure animals from common parasitic diseases.

Materials and methods

Ethics approval and consent to participate

This study was conducted in compliance with institutional and national regulations. The study protocol was reviewed and approved by the Institutional Ethics Committee of the “Institut de Recherche en Sciences de la Santé” (IEC-IRSS) and registered as N˚A06/2016/ CEIRES.

Anopheles coluzzii VK5 strain

A colony of one of the major vectors of Plasmodium, An. Coluzzii [33], was used in this study. The colony was established in year 2008 from 200 wild blood-fed females captured inside houses using a mouth aspirator at the Kou Valley (11° 23′14 ″ N, 4° 24′42 ″ W) near Bobo-Dioulasso, South-Western Burkina Faso, was used in this study. It is the same than one used for the study published by Pooda et al. 2015 [34], with a proportion of 30–40% mosquitoes carrying the kdr-resistant allele conferring resistance to pyrethoids. It was repeatedly replenished with F1 from wild-caught mosquito females collected in the same area. The species composition of the colony, its resistance to insecticides status and potential contamination by other species or strains was routinely checked using PCR assay as previously described [34]. The strain was maintained in the “Institut de Recherche en Sciences de la Santé” (IRSS) insectary in Bobo-Dioulasso. The insectary’ conditions were: a temperature of 27 ± 2°C, relative humidity of 75 ± 5% and a 12h/12h light/dark photoperiod.

Experimental animals

This work was carried out using sheep, pigs, and goats purchased from surrounding farms near Bobo-Dioulasso, and transported to the Centre International de Recherche-Développement sur l’Elevage en zones subhumides (CIRDES) experimental barns. The sheep and goats belonged to the Djallonké breed, which is widespread in the study area, while the pigs were of local breed. All animals were dewormed using albendazole (one bolus of 2500 mg of albendazole per animal) one month before the start of the experiment. Additionally, the sheep were treated with a curative trypanocidal (Veriben®) at the prescribed dose of 3.5 mg/kg to clear trypanosome parasites responsible for African Animal Trypanosomiasis, a common disease affecting this species in South-Western Burkina Faso.

The average animal weight at the time of the experiment was 21 ± 3kg for sheep (n = 6), 14 ± 1.65kg for goats (n = 6) and 35 ± 5kg for pigs (n = 8). Water and mineral salts were provided to the animals ad libitum throughout the study period. The sheep were fed with rice straw and cottonseed cake at 500 g per day. Three to four kg per day of a concentrate food compound manufactured by the “Centre de Promotion de l’Aviculture Villageoise” (CPAVI) and composed mainly of corn, cottonseed cake, and essential amino acids were given to the pigs. Herbaceous legumes (given at libitum) and cottonseed cake (500 g per day) were offered to goats.

The injectable veterinary ivermectin formulation (IVOMEC-D®, Boehringer Ingelheim, Lyon, France) was used. This drug contains 1% ivermectin and 10% Clorsulon as active ingredients. IVOMEC-D® targets mainly gastrointestinal nematodes, strongyles, lungworms, and external parasites in cattle and sheep. Clorsulon targets liver flukes. We tested the mosquitocidal effect of blood meals taken by Anopheles coluzzii females on hosts treated using the recommended therapeutic dose of the product, which varies according to the animal species: 0.2, 0.3, and 0.4 mg/kg of body weight for sheep, pigs, and goats, respectively. With the pigs, our preliminary data (S1 File) showed only a limited effect of the recommended dose, so two other doses (0.6 mg/kg and 0.9 mg/kg) were also tested. The drug was administered through a single subcutaneous injection into the collier of each animal.

For each species, animals were randomly allocated to the control or experimental groups. The number of animals per group and the number of groups per species are presented in Table 1.

Table 1. Distribution of animal species between control and ivermectin-treatment groups.

Animal species Ivermectin treatment (dose, mg/kg) Number of animals
per treatment
Date of injection
Sheep Ctrl (0) 3 19/09/2017
TD (0.2) 3
Goat Ctrl (0) 3 01/04/2017
TD (0.4) 3
Pig Ctrl (0) 2 28/08/2018
TD (0.3) 2
2TD (0.6) 2
3TD (0.9) 2

Ctrl: Control; TD: Therapeutic dose.

The study was realized sequentially: goats were treated in April 2017, sheep in September of the same year, and pigs in August 2018. Batches of mosquitoes were exposed accordingly.

Mosquito bioassays

Mosquito blood-feeding bioassays were performed as previously described [34,35]. Briefly, three to five-day-old female An. coluzzii mosquitoes were starved for 24 hours before the exposure experiment to increase their appetence for hosts. A circular area was shaved on the flank of each animal to facilitate mosquito feeding. Starved An. coluzzii were transferred into plastic cups covered with a net (large radius = 85 mm, small radius = 43 mm, height = 80 mm) and held using a rubber band on the flank of the animal. During the direct skin feeding assays that took place in the morning (between 08:00 a.m. and 11:00 a.m.), animals were restrained using ropes to avoid rough movements and scratching. Mosquitoes were allowed to feed on the shaved animal spots for 30 minutes.

All mosquitoes fed on the same animal were transferred in a large cage from which mosquitoes were individually aspirated using a mouth aspirator and sequentially put in the cups (cup 1 to 4 and then back again to cup 1) until cups were completed to 10 mosquitoes each. All cups were put in trays, and on a shelf, in the insectary. Each day, the cups were taken from the trays, observed for mosquito mortality and put back. To avoid confounding positional effect on mosquito mortality and fecundity phenotypes, trays were rotated from shelf to shelf, and cups inside the trays as well. All the cups were maintained in the same insectary.

Experimental design for survival, gravidity rate and egg production evaluations

In order to evaluate the effect of ivermectin on survival and fecundity of An. coluzzii, the same batches of around 118 (± 65) Anopheles were allowed to feed on each treated and control animal before treatment (0 day) and at different time points (2, 7, 14, 21, and 28 days) after injection (DAI)). Only fully fed females were considered for survival and fecundity follow-ups. For survival, 40 fed females per each host individual and each time point were randomly distributed in 4 paper cups (ten mosquitoes per cup) and provided every day with cotton balls soaked in a 2.5% glucose solution. Mortality was recorded every day between 8 and 10 a.m. in the morning from the day of blood feeding until all mosquitoes died. Mosquitoes were considered dead if they were lying on the bottom of the cup and unable to move.

Since the first blood meal in Anopheles gambiae s.l. mosquitoes is often used to compensate for nutritional deficiencies carried over from larval stages instead of developing ovarian follicles [36,37], the number of eggs produced after two consecutive blood meals is usually considered more representative of actual mosquito fecundity. Thus, for fecundity measurements, remaining female mosquitoes from the first blood feeding were given a second blood meal on the same host 3 days after the first one. Only females that had actually taken two blood meals were further considered. Dissection of the ovaries was performed 4 days later, when the entire digestion of the second blood meal had occurred. Ovaries were extracted from the mosquito abdomen and dissected in a drop of Phosphate-Buffered Saline (PBS) to release the eggs. Eggs were then counted under a binocular (40×, Leica S6D). The proportion of females carrying developed eggs (gravidity rate) and the number of mature eggs (i.e., those that reached Christopher stage V of ovarian development) [38] were considered as proxies of mosquito fecundity, are proxies representing important parameters of the mosquitoes reproductive potential.

Dosage of ivermectin in animal blood samples

Blood samples from experimental animals were collected in Heparin tubes through the jugular vein using a syringe and a 21-gauge needle. Blood samples were centrifuged at 1500 rpm for 15 min, and the plasma was aliquoted in 1.5 ml Eppendorf tubes and stored at -20°C until analysis.

Ivermectin extraction and quantification by high-performance liquid chromatography (HPLC) with fluorescence detection after derivatization were performed as previously described [39,40]. First, 1 ml thawed plasma was transferred into a 15 ml polypropylene vial. This was fortified with 25 μl of a 2000 ng/ml doramectin internal standard solution and 3 ml of cold (-32°C) HPLC-grade acetonitrile (ACN). After ultrasound-assisted extraction and subsequent centrifugation, an aliquot of the supernatant was evaporated under N2 and reconstituted in 600 μl ACN. This was filtered (0.45 μm, polytetrafluoroethylene), and for HPLC-fluorescence detection, ivermectin was derivatized with N-methylimidazole/ACN (1:1, v/v), triethylamine, trifluoroacetic anhydride/ACN (1:1, v/v), and trifluoroacetic acid. Samples were quantified on an Agilent 1200 HPLC system with a C18 column and a gradient elution (purified Milli-Q® water and ACN). Ivermectin concentrations were corrected with doramectin as a surrogate, representing the recovery rate during analysis. Mean IVM recovery (n = 122 samples) ± relative standard deviation in plasma was 86.8 ± 17.6%.

Statistical analysis

All statistical analyses were performed using the R software, version 1.2.5033 [41].

Blood feeding rate were estimated using general linear models (GLM) using the ‘glm’ and ‘glmmTMB’ functions [42] with binomial distribution of the error. Exposed mosquito were used as dependent variable, and treatments, DAI, and interactions were used as explanatory variables.

The survival of Anopheles was analyzed using Cox proportional hazard model with treatments, the DAIs (coded as a categorical variable) and interaction as explanatory variables. The model was fitted using the ‘coxph’ function of the ‘survival’ package [43]. Theses analyzes were done for each animal blood source.

To assess the individual animal effect on mosquitoes mortality, a Cox model was fitted on data at DAI = 0 (before injection) with individual animals as the explanatory variable.

Gravidity and egg production were estimate using general linear models (GLM) were fitted using the ‘glm’ and ‘glmmTMB’ functions [42], respectively, with the binominal and negative binomial distribution of the error. The gravidity status and the number of eggs recorded for each individual mosquito were used as dependent variables, and treatments, DAI, and interactions were used as explanatory variables.

Hazard ratios, odd ratios, rate ratios and their 95% confidence intervals were produced using the ‘emmeans’ function [44].

Results

All data supporting these results are available in the supporting information S3S5 Files.

Blood feeding rate

There was no effect of the treatment of ivermectin on the rate of mosquitoes blood-fed on sheep (χ21 = 0.0867, P = 0.77), goats (χ21 = 0.1071, P = 0.74) and on pigs (χ23 = 2.5833, P = 0.46), with no significant difference between mosquitoes fed on corresponding treated and control animals (S1 Table). All samples taken together, the rate of blood-fed mosquitoes during the first blood meal was, respectively, 71.52 (±4.88) %, 71.94 (±3.15) % and 57.46 (±2.55) % on sheep, goat and pig (Fig 1), and was, for the second blood meal they were respectively 59.57 (±4.55) %, 58.26 (±5.53) %, and 69.46 (±2.74) %, on sheep, goat and pig. The sample size for each mosquito group is given in the S1 Table. The proportion of bloodfed mosquitoes on pigs is overall lower than on the other animals.

Fig 1. Rate of blood-fed Anopheles coluzzii according to host specie and ivermectin treatment.

Fig 1

TD = therapeutic dose for the given host species; 2TD = double therapeutic dose; Triple therapeutic dose.

Survival

The effects of ivermectin on An. coluzzii survival were analyzed using a total of 5 590 blood-fed females, with 986, 1 397, and 3 207 female Anopheles fed on sheep, goats, and pigs, respectively. Before the treatment, and for each specie, An. coluzzii survival was not significantly different between the controls and experimental groups (group effect: sheep, χ 21 = 7.60, P = 0.18; goats: χ21 = 0.003, P = 0.96; pigs: χ23 = 2.99; P = 0.39) (Fig 2).

Fig 2. Kaplan Meir Survival curves of An. coluzzii after blood-feeding, displayed by treatment, host species and days after injection.

Fig 2

DAI: Days after injection; TD = therapeutic dose for the given host species.

Overall, the Cox proportional hazard model showed that ivermectin injected at the therapeutic dose negatively impacted survival of mosquitoes that fed on treated sheep (Treatment effect: χ 21 = 24.68, P < 0.001), goats (Treatment effect: χ 21 = 18.34, P<0.001), and pigs (Treatment effect: χ 21 = 49.80, P < 0.001). The doubled and tripled therapeutic doses used to treat pigs induced as well a significant decrease in mosquito mortality rates (Treatment effect: χ 21 = 24.85, P < 0.001 for double dose, χ 21 = 136.46, P < 0.001 for triple dose). Mortality of An. coluzzii also significantly varies according to the delay post-ivermectin injection at which blood feeding occurred on treated sheep (DAI effect: χ 25 = 175.16, P<0.001), goats (DAI effect: χ 25 = 321.88, P < 0.001) and pigs (DAI effect: χ 25 = 462.36, P<0.001). Furthermore, the interaction between effects of the treatment and the DAI was significant (treated sheep (Treatment x DAI effect: χ 25 = 93.67, P<0.001), goats (Treatment x DAI effect: χ 25 = 35.28, P<0.001), and pigs (Treatment x DAI effect: χ 25 = 253.99, P<0.001). Specifically, the administration of IVM led to a marked reduction in mosquito survival at DAI 2 and 7 when compared to the control group, but there was no discernible difference from DAI 14 to 28.

Accordingly, calculated hazard ratios (HR) showed a significantly higher probability of dying for mosquitoes fed on hosts treated using the therapeutic dose 2 days after injections in sheep (HR = 5.56, IC [4.08–8.90], P < 0.001), goats (HR = 1.44, IC [1.11–1.88]; P = 0.006) and pigs (HR = 2.42, IC = [1.59–3.68]; P < 0.001) (Fig 2). At this timepoint, the median survival time was reduced by 75, 22.2 and 83.0% in mosquitoes fed on treated sheep, goats and pigs, respectively, compared to those fed on control groups.

The effect of the treatment remained significant at 7 DAI in sheep (HR = 2.72, IC [1.99–3.72], P < 0.001), goats (HR = 2.95, IC [2.27–3.84], P < 0.001) and pigs (HR = 9.35, IC = [5.98–14.64]; P < 0.001) (Fig 2). The median survival time at this delay post treatment was reduced by 48.8, 66.7, and 89.7% when female An. coluzzii fed on treated sheep, goats and pigs, respectively, compared to mosquitoes fed on the control groups. From day 14 post-treatment and onwards, there was no significant difference between groups whatever the host species considered (Fig 2).

Considering the doubled therapeutic dose (0.6 mg/kg) that was attributed to pigs, Anopheles survival was impacted at 7 DAI only (HR = 6.65, IC [4.28–10. 34]; P < 0.001; Fig 2), with an 89.7% decrease in female survival time when fed on treated pigs compared to the controls. Treatment with the triple therapeutic dose (0.9 mg/kg) provoked significant higher mortality in mosquitoes lots fed at 2 DAI (HR = 4.98, IC [3.30–7.53], P<0.001) and 7 DAI (HR = 15.75, [9.94–24.94], P <0.001), and extended the mosquitocidal effect until 14 DAI (HR = 2. 71, IC [1.79–4.10]; P < 0.001). Compared to mosquitoes fed on control pigs, the decrease in survival was 88.89%, 93.10% and 68.97% for An. coluzzii mosquitoes fed on treated ones (data for DAI of 2, 7 and 14, respectively).

Gravidity

Overall, 2,373 gravid females An. coluzzii were dissected after two successful blood meals, with 652 and 938 females fed on sheep and goats, respectively. Sample sizes obtained for pigs did not allow further analysis. (S1 Table and S2 File). Gravidity rates (proportion of females carrying developed eggs) according to the blood meal origin and DAI are shown in Fig 3.

Fig 3.

Fig 3

Gravidity rates of female An. coluzzii after two successful blood meals on control (gray) and ivermectin- (orange) treated sheep and goats at day(s) 0, 2, 7, 14, 21, and 28 post-treatments. Error bars correspond to the Standard Error.

Before the treatment, gravidity rates of females An. coluzzii were similar between the control and treated groups of sheep and goats (all P > 0.05).

Treatment of sheep and goats with their respective therapeutic dose of ivermectin had a significant impact on An. coluzzii gravidity rate. Indeed, for An. coluzzii that fed on treated sheep, gravidity rates were reduced, compared to those fed on controls, by 32.57 and 42.03% at 2 DAI (OR = 4.78, IC [1.60–2.80], P = 0.005) and 7 DAI (OR = 3.90, IC [1.42–10.71], P = 0.008) respectively. Similarly, treatment of goats with ivermectin led to a 28.28 and 73.64% reduction of An. coluzzii gravidity rate in treated group compared to control at 2 DAI (OR = 2.13, IC [1.06–4.31], P = 0.03) and 7 DAI (OR = 5.92, IC [2.70–12.96], P < 0.001) respectively. No significant decreasing effect of treatment was observed at 14, 21 or 28 DAI (Fig 3). However, an unexpected 39.76% significant increase in gravidity rate was observed in An. coluzzii that fed on treated-goats at 28 DAI compared to those fed on control animals (79.41% ± 6.93% vs 56.82% ± 7.46% in the control group, Fig 3, OR = 0.34, IC [0.123–0.949], P = 0.04)).

Development of mature eggs

Before the injection of ivermectin, the mean number of developed mature eggs by female An. coluzzii that fed on control and treated sheep (140.17 vs. 145.13 eggs/female) and goats (161.02 vs. 147.47 eggs/female) was not significantly different (Fig 4).

Fig 4. Average number of developed eggs by gravid female An. coluzzii according to blood meal origin (sheep or goat), DAI and treatment.

Fig 4

Error bars correspond to the Standard Error.

In sheep, a significant decrease of the mean number of eggs developed by female was observed at 28 DAI only, with a mean number of eggs decreasing from 137.4 (±16.8) eggs/female in the control group to 93.4 (±10.15) eggs/female in the treated group (Fig 4). This represents a 32.06% decrease in egg production (OR = 1.45, IC [1.07–2.03], P = 0.02). A similar trend was observed at 7, 14, and 21 DAI, but was not significant.

In goats, injection of ivermectin at a dose of 0.4 mg/kg led to a significant decrease in the mean number of eggs developed by a female An. coluzzii fed on treated animals compared to controls at 7 DAI (OR = 1.55, IC [1.02–2.37]; P = 0.04) and 14 DAI (OR = 1.48, IC [1.04–2.09]; P = 0.03), with a 35.7% and 32.2% decrease in egg production, respectively (Fig 4).

Ivermectin plasma concentration in treated animals

Table 2 shows the mean plasma concentrations of ivermectin in sheep, goats, and pigs according to treatment and DAI. The single timepoint at which ivermectin concentration was assessed in sheep precludes any consideration of the concentration dynamics for this species. Analyses revealed that plasma concentrations in goats and pigs were relatively constant and reached a peak between day 2 and day 7 post-treatment. Following that, ivermectin concentrations decreased toward low or undetectable levels, depending on the treated host and treatment dose. Interestingly, ivermectin plasma concentrations were 2 to 5-fold higher in pigs compared to goats at all timepoints, regardless of the dose (Table 2). For pigs in particular, a great inter-individual host variability in ivermectin plasma concentration can be noticed.

Table 2. Median plasma concentrations of ivermectin (ng/mL) in the treated- sheep, goats and pigs according to the DAI.

Species Dose [mg/kg] Median (Min–Max) plasma concentration of ivermectin (ng/ml) according to the DAI
2 7 14 21
Goat (n = 3) 0.40 6.4 (0–7.8) 9.00 (6.7–12.4) 0.0 (0–3.7) -
Pig (n = 2 per Dose) 0.30 22.50 (11.7–33.3) 20.65 (19.5–21.9) 6.5 (6.2–6.8) 0
0.60 20.35 (7.6–33.1) 27.55 (23.3–31.8) 12.25 (6.2–18.3) 2 (0–4)
0.90 40.45 (32.9–48) 33.85 (32.6–35.1) 10. 7 (9.5–11.9) 4.95 (3.8–6.1)
Sheep (n = 3) 0.20 - 6.00 (5.7–6.3) - -

Discussion

The presence of alternative blood sources (i.e. cattle, sheep, goats, pigs, dogs …) to human allows zoophagic and opportunistic Anopheles mosquitoes to maintain and continue to transmit malaria despite high population coverage using LLINs and IRS [27,45,46]. However, this feeding behavior may provide an opportunity for zooprophylaxis and to controlling these malaria vectors using the insecticide-treated livestock (ITL) strategy [13]. Herein, we investigated the impact of ivermectin-treated sheep, goats and pigs on the survival and the production of mature eggs of An. coluzzii, major vector of Plasmodium throughout western Africa. The results demonstrated that ivermectin treatment of each animal species at the therapeutic dose reduced the survival and eggs production of An. coluzzii. The survival of An. coluzzii was decreased by 89.7, 66.7, and 48.4% when fed on treated pigs, goats, and sheep, respectively at 7 DAI, comparatively to those fed on untreated animals. In addition, female An. coluzzii that did survive after feeding on treated animals exhibited a reduced number of eggs developed (32% reduction for mosquitoes that fed on sheep at 28 DAI and 35.65% and 32.21% for those fed on goats respectively at 7DAI and 14 DAI). At therapeutic doses, toxicity to survival seemed higher in pigs compared to goats and sheep, although significance of this comparison is loose because studies in pigs were performed at separate time periods, using different mosquito batches. However, ivermectin plasma concentration measurements clearly revealed that ivermectin availability in the host bloodstream differed between species. This is especially evident when comparing pigs and goats, with the former displaying the highest ivermectin plasma level at all considered timepoints although they received the lowest therapeutic dose. Our results are consistent with those reviewed by Alvinerie and al. [47] and they may be explained by species-specific parameters that impact the pharmacokinetic properties of ivermectin in a given organisms, as the absorption process, the volume of distribution of the molecule, the different body compartments where the molecule is actually distributed, the lean vs fat weight as ivermectin is highly hydrophobic, the metabolism of the considered species and the metabolization of ivermectin into secondary metabolites [4749]. These parameters actually determine quantitatively and qualitatively the molecule’s distribution in the different body compartments including the skin’s blood capillaries where the mosquitoes bite. Our data show that mosquitocidal efficacy for a given ivermectin plasma concentration differs from a species to another and that inter-species extrapolations of efficacy or effectiveness based on plasma ivermectin concentrations only are not meaningful. Lethal plasma concentrations should therefore be estimated at the least for each species.

Differences in pharmacokinetics properties among species is also illustrated by differential duration of the lethal effect of the therapeutic dose, which is 7 days in our study for sheep, goats and pigs, but is longer lasting for cattle (3 weeks post-treatment, shown suing the same experimental approach [34]).

Mosquitocidal efficacy and plasma concentrations data in pigs receiving the therapeutic dose are in line with previous studies [20]. Increasing treatment doses did not lead to a proportional rise in median plasma ivermectin concentrations, nor in efficacy. For this species, significant data variability was observed among animals within the same treatment groups, and the small number of pigs per group clearly limits our study. However, this same design has also been used in other studies [20,35].

The proportion of blood-fed mosquitoes was lower in pigs compared to sheep and goats (Fig 2). This may be due to thicker skin and increased agitation and skin tremors observed in pig during feeding assays, which can be seen as defensive behavior against blood-feeing ectoparasites like Anopheles [50]. This behavior could lead to less effective blood meals, although our observations of engorged females did not show any noticeable differences. However, in the field, the proportion of Anopheles coluzzii feeding on pigs might be higher since defensive behaviors are naturally reduced at night, when main Plasmodium vectors are active.

Sub-lethal ivermectin plasma concentrations also impaired gravidity rate and fecundity, expressed as the number of eggs developed in mosquitoes ovaries, when female Anopheles blood fed on ivermectin-treated sheep and goats. Such reduction in fecundity potential is in line with numerous previous studies [21,34,51]. These sub-lethal effects on vectors reproductive outputs would, in the fields, translate into greater and/or prolonged efficacy at decreasing Anopheles densities, and woul sustain decreasing Plasmodium transmission. Current models used to predict ivermectin mass administration impacts on Plasmodium transmission and malaria epidemiology focus on mosquito survival data only and, therefore, probably underestimate the ability of this drug to be a powerful complementary vector control tools. Taking into account reproductive outputs in future models would allow a more complete comprehensive projection of potential impacts of ivermectin-based zooprohylaxy approach.

Our present and past results [34] demonstrated that ivermectin treatments of the main livestock species in rural endemic Africa significantly reduce the fitness of Anopheles vector under laboratory conditions. Scaling-up such approach in the field will require a better understanding of the molecule pharmacokinetics and pharmacodynamics for all the Anopheles host species, as well as a better characterization of the blood feeding preference of these vectors in the fields. Innate feeding preferences does not necessarily reflect the actual realized bloodmeal [7,27], which depends on the relative proportions of the different host and their accessibility to mosquitoes. The proportion of opportunistic mosquitoes from major vectors species is likely underestimated in the fields, so is the role domestic animals play in maintaining their populations and the residual Plasmodium transmission despite optimal control tools deployment. Moreover, bloodmeals origin assessments suffer from sampling challenges of outdoor feeding mosquitoes, a feeding trait often associated with zoophagy [13]. In Burkina Faso, rural communities live in close proximity to cattle, as well as sheep, goats, and pigs [52]. Cattle are the preferred alternative hosts for An. gambiae s.l. populations [7,27], but the number of sheep and goats can far exceeds that of cattle, potentially leading to more mosquitoes targeting these animals as alternative hosts. Pigs are primarily found in the southwestern region, where their densities are the lowest compared to the other species. Therefore, in areas where ivermectin-based interventions are planned, it is essential to thoroughly assess blood indexes in malaria mosquito populations, conduct a census of the different host species, and perform species-specific pharmacokinetics and pharmacodynamics studies to predict effectiveness accurately. This also involves determining the duration of significant mortality effects for each mosquito species.

The effectiveness of this approach also depends on timely interventions, particularly at the onset of the rainy season to prevent mosquito populations from increasing exponentially [53], and on using appropriate treatment schemes and doses. This includes utilizing long-lasting technologies to maintain ivermectin blood concentrations at effective levels throughout the Plasmodium transmission season [35,54,55], while easing the logistics of multiple dosing schemes.

The treatment coverage and overall implementation of the approach will inevitably be constrained by the ivermectin usage guidelines established by the Joint FAO/WHO Expert Committee on Food Additives [56], particularly concerning milk and slaughter withdrawal periods. The benefits to animal health and the long-term wealth of herders must be balanced against potential short-term resource shortages. Therefore, the number of animals to be treated should be determined in consultation with herders, using integrative models to ensure that effectiveness is achieved. Interestingly, not treating entire herds will create refugia for susceptible endo and ectoparasites including Anopheles vectors, providing mitigation strategy against ivermectin resistance [57,58]. This same constraint also provides refugia for non-targeted fauna including coprophagic organisms. However, environmental risk assessments should be conducted, and mitigation measures implemented, to ensure the sustainability of this approach and to protect already fragile ecosystems and agro-ecosystems, where manure plays a crucial role in soil fertilization [55,59].

Conclusions

The present study shows that ivermectin-treated sheep, goats, and pigs, using the prescribed dose for each species, reduce the survival and fecundity potential of the opportunistic malaria vector Anopheles coluzzii under laboratory conditions. However, the limited period of efficacy questions the practical feasibility of using this veterinary formulation in the fields, because the logistical and cost issues for providing sufficient coverage to span the whole transmission season. Overcoming these limitations will require the use, for instance, of slow-release technologies that allow sustained efficacy for more than a month, as recommended by the WHO for endectocides approaches in malaria vector control. Such an integrated intervention, in the One-Health frame, would address the so far neglected aspect of Plasmodium transmission that involves domestic animals. Opportunistic, major malaria vectors feed on these readily accessible alternative hosts, which allow residual transmission to occur despite high control tool coverage. Endemic countries carrying the highest malaria burden are in their vast majority also countries where human and domestic animal populations lives are intricated. Such an approach, if environmental concerns are also addressed, will likely allow such malaria endemic countries to get closer from their development goals in terms of both health and wealth.

Supporting information

S1 Table. Number of exposed, blood-fed and dissected female Anopheles according to the hosts species, the treatment and the time elapsed since the injection (DAI).

(PDF)

pone.0308293.s001.pdf (165KB, pdf)
S1 File. Preliminary study: Efficacy of blood meal taken on treated pigs with therapeutic dose of ivermectin on the survival of Anopheles coluzzii.

(PDF)

pone.0308293.s002.pdf (197.7KB, pdf)
S2 File. Gravidity rate and fecundity in females Anopheles coluzzii fed on pig.

(PDF)

pone.0308293.s003.pdf (271.9KB, pdf)
S3 File. Data set on the bloodmeal rate of Anopheles coluzzii.

(TXT)

pone.0308293.s004.txt (19.7KB, txt)
S4 File. Data set on the survival of Anopheles coluzzii.

(TXT)

pone.0308293.s005.txt (314.7KB, txt)
S5 File. Data set on the gravidity status and the number of eggs developed in Anopheles coluzzii.

(TXT)

pone.0308293.s006.txt (131.4KB, txt)

Acknowledgments

This paper is in Memory of Jean-Baptiste Rayaissé and Issa Sidibé who were one of the main actors of this work and who passed away! Rest in peace!

We thank sincerely the Merial laboratory which graciously gave us the ivermectin-based medicine, as well as all the technicians and animal keepers who helped us in carrying out this work.

Data Availability

All data supporting these results are available in the Supporting Information S3 File to S5 File.

Funding Statement

This experimental study was supported by the REACT project founded by the “Expertise France” and the LAMIVECT (LAboratoire Mixte International sur les Maladies à VECTeurs) founded by the Institut de Recherche pour le Développement (IRD).

References

  • 1.World Health Organization. World malaria report 2021: Tracking progress against malaria. Geneva, Switzerland: World Health Organization; 2021. [Google Scholar]
  • 2.World Health Organization. World malaria report 2022. Geneva, Switzerland: World Health Organization; 2022. [Google Scholar]
  • 3.Killeen GF. Characterizing, controlling and eliminating residual malaria transmission. Malar J. 2014;13: 330. doi: 10.1186/1475-2875-13-330 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Russell TL, Beebe NW, Cooper RD, Lobo NF, Burkot TR. Successful malaria elimination strategies require interventions that target changing vector behaviours. Malar J. 2013;12: 56. doi: 10.1186/1475-2875-12-56 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Perugini E, Guelbeogo WM, Calzetta M, Manzi S, Virgillito C, Caputo B, et al. Behavioural plasticity of Anopheles coluzzii and Anopheles arabiensis undermines LLIN community protective effect in a Sudanese-savannah village in Burkina Faso. Parasit Vectors. 2020;13: 277. doi: 10.1186/s13071-020-04142-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Sinka ME, Bangs MJ, Manguin S, Coetzee M, Mbogo CM, Hemingway J, et al. The dominant Anopheles vectors of human malaria in Africa, Europe and the Middle East: occurrence data, distribution maps and bionomic précis. Parasites & Vectors. 2010;3: 117. doi: 10.1186/1756-3305-3-117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Lefèvre T, Gouagna L-C, Dabiré KR, Elguero E, Fontenille D, Renaud F, et al. Beyond nature and nurture: phenotypic plasticity in blood-feeding behavior of Anopheles gambiae s.s. when humans are not readily accessible. Am J Trop Med Hyg. 2009;81: 1023–1029. doi: 10.4269/ajtmh.2009.09-0124 [DOI] [PubMed] [Google Scholar]
  • 8.Pombi M, Calzetta M, Guelbeogo WM, Manica M, Perugini E, Pichler V, et al. Unexpectedly high Plasmodium sporozoite rate associated with low human blood index in Anopheles coluzzii from a LLIN-protected village in Burkina Faso. Sci Rep. 2018;8: 12806. doi: 10.1038/s41598-018-31117-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Padonou GG, Zoungbédji DM, Sovi A, Salako AS, Konkon AK, Yovogan B, et al. Trophic preferences of Anopheles coluzzii (Diptera: Culicidae): what implications for malaria vector control in Benin? ment. 2023;60: 554–563. doi: 10.1093/jme/tjad017 [DOI] [PubMed] [Google Scholar]
  • 10.Ngufor C, Agbevo A, Fagbohoun J, Fongnikin A, Rowland M. Efficacy of Royal Guard, a new alpha-cypermethrin and pyriproxyfen treated mosquito net, against pyrethroid-resistant malaria vectors. Sci Rep. 2020;10: 12227. doi: 10.1038/s41598-020-69109-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Tiono AB, Ouédraogo A, Ouattara D, Bougouma EC, Coulibaly S, Diarra A, et al. Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-randomised controlled trial. The Lancet. 2018;392: 569–580. doi: 10.1016/S0140-6736(18)31711-2 [DOI] [PubMed] [Google Scholar]
  • 12.AMP. 2022 Net Mapping Project report. Geneva, Switzerland: The Alliance for Malaria Prevention; 2022. [Google Scholar]
  • 13.Ruiz-Castillo P, Rist C, Rabinovich R, Chaccour C. Insecticide-treated livestock: a potential One Health approach to malaria control in Africa. Trends Parasitol. 2022;38: 112–123. doi: 10.1016/j.pt.2021.09.006 [DOI] [PubMed] [Google Scholar]
  • 14.Tusting LS, Ippolito MM, Willey BA, Kleinschmidt I, Dorsey G, Gosling RD, et al. The evidence for improving housing to reduce malaria: a systematic review and meta-analysis. Malaria Journal. 2015;14: 209. doi: 10.1186/s12936-015-0724-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Traore MM, Junnila A, Traore SF, Doumbia S, Revay EE, Kravchenko VD, et al. Large-scale field trial of attractive toxic sugar baits (ATSB) for the control of malaria vector mosquitoes in Mali, West Africa. Malar J. 2020;19: 72. doi: 10.1186/s12936-020-3132-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Antonio-Nkondjio C, Doumbe-Belisse P, Djamouko-Djonkam L, Ngadjeu CS, Talipouo A, Kopya E, et al. High efficacy of microbial larvicides for malaria vectors control in the city of Yaounde Cameroon following a cluster randomized trial. Sci Rep. 2021;11: 17101. doi: 10.1038/s41598-021-96362-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Fritz ML, Siegert PY, Walker ED, Bayoh MN, Vulule JR, Miller JR. Toxicity of bloodmeals from ivermectin-treated cattle to Anopheles gambiae s.l. Ann Trop Med Parasitol. 2009;103: 539–547. doi: 10.1179/000349809X12459740922138 [DOI] [PubMed] [Google Scholar]
  • 18.Dreyer SM, Morin KJ, Vaughan JA. Differential susceptibilities of Anopheles albimanus and Anopheles stephensi mosquitoes to ivermectin. Malar J. 2018;17: 148. doi: 10.1186/s12936-018-2296-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Chaccour CJ, Ngha’bi K, Abizanda G, Irigoyen Barrio A, Aldaz A, Okumu F, et al. Targeting cattle for malaria elimination: marked reduction of Anopheles arabiensis survival for over six months using a slow-release ivermectin implant formulation. Parasit Vectors. 2018;11: 287. doi: 10.1186/s13071-018-2872-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Pasay CJ, Yakob L, Meredith HR, Stewart R, Mills PC, Dekkers MH, et al. Treatment of pigs with endectocides as a complementary tool for combating malaria transmission by Anopheles farauti (s.s.) in Papua New Guinea. Parasit Vectors. 2019;12: 124. doi: 10.1186/s13071-019-3392-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Gardner K, Meisch M V., Meek CL, Biven WS. Effects of ivermectin in canine blood on anopheles quadrimacularus, Aedes albopictus and Culex salinarius. Journal of the American Mosquito Control Association. 1993;9: 400–402. [PubMed] [Google Scholar]
  • 22.Saul A. Zooprophylaxis or zooptentiation: the outcome of introducing animals on vector transmission in highly dependent on the mosquito mortality while searching. Malaria Journal. 2003;2: 1–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Donnelly B, Berrang-Ford L, Ross NA, Michel P. A systematic, realist review of zooprophylaxis for malaria control. Malaria Journal. 2015;14: 313. doi: 10.1186/s12936-015-0822-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Morona D, Mazigo H, Kimaro EE, Kweka E. Zooprophylaxis: a stragtegy for effective delivery of endectocides for vector control. Journal of Transmitted Diseases and Immunity. 2017;1. doi: 10.21767/2573-0320.100013 [DOI] [Google Scholar]
  • 25.World Health Organization, United Nations Children’s Fund. Achieving the malaria MDG target: reversing the incidence of malaria 2000–2015. Geneva, Switzerland: World Health Organization and the United Nations Children’s Fund; 2015. Available: https://apps.who.int/iris/bitstream/handle/10665/184521/9789241509442_eng.pdf;jsessionid=4CFA4FD9239E58EC7EB279209057E1E5?sequence=1. [Google Scholar]
  • 26.World Health Organization. The potential impact of health service disruptions on the burden of malaria: a modeling analysis of countries in sub-Saharan Africa. Geneva, Switzerland: World Health Organization; 2020. Available: file:///C:/Users/HP/Downloads/WMD-Covid_2020_DataSnapshot_BFA.pdf. [Google Scholar]
  • 27.Vantaux A, Moiroux N, Dabiré KR, Cohuet A, Lefèvre T. Multiple hosts, multiple impacts: the role of vertebrate host diversity in shaping mosquito life history and pathogen transmission. Peer Community Journal. 2023;3: e54. doi: 10.24072/pcjournal.288 [DOI] [Google Scholar]
  • 28.Imbahale SS, Montaña Lopez J, Brew J, Paaijmans K, Rist C, Chaccour C. Mapping the potential use of endectocide-treated cattle to reduce malaria transmission. Sci Rep. 2019;9: 5826. doi: 10.1038/s41598-019-42356-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Lo PK, Fink DW, Williams JB, Blodinger J. Pharmacokinetic studies of ivermectin: effects of formulation. Vet Res Commun. 1985;9: 251–268. doi: 10.1007/BF02215150 [DOI] [PubMed] [Google Scholar]
  • 30.Fink DW, Porras AG. Pharmacokinetics of Ivermectin in Animals and Humans. In: Campbell WC, editor. Ivermectin and Abamectin. New York, NY: Springer; 1989. pp. 113–130. doi: 10.1007/978-1-4612-3626-9_7 [DOI] [Google Scholar]
  • 31.Chaccour CJ, Kobylinski KC, Bassat Q, Bousema T, Drakeley C, Alonso P, et al. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J. 2013;12: 153. doi: 10.1186/1475-2875-12-153 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Kobylinski KC, Ubalee R, Ponlawat A, Nitatsukprasert C, Phasomkulsolsil S, Wattanakul T, et al. Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles. Malar J. 2017;16: 280. doi: 10.1186/s12936-017-1923-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Epopa PS, Collins CM, North A, Millogo AA, Benedict MQ, Tripet F, et al. Seasonal malaria vector and transmission dynamics in western Burkina Faso. Malar J. 2019;18: 113. doi: 10.1186/s12936-019-2747-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Pooda SH, Rayaissé J-B, Hien DF de S-H, Lefèvre T, Yerbanga SR, Bengaly Z, et al. Adminsitration of ivermectin to peridomestic cattle: a promising approach to target the residual transmission of human malaria. Malar J. 2015;14. doi: 10.1186/s12936-015-1001-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Pooda SH, Moiroux N, Porciani A, Courjaud A-L, Roberge C, Gaudriault G, et al. Proof-of-concept study for a long-acting formulation of ivermectin injected in cattle as a complementary malaria vector control tool. Parasit Vectors. 2023;16: 66. doi: 10.1186/s13071-022-05621-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Brengues J, Coz J. Quelques aspects fondamentaux de la biologie d’Anopheles gambiae Giles (Sp. A.) et d’Anopheles funestus Giles, en zone de savane humide d’Afrique de l’Ouest. Cah ORSTOM, sér Ent méd et Parasitol. 1973;XI: 107–126. [Google Scholar]
  • 37.Mouline K, Mamai W, Agnew P, Tchonfienet M, Brengues C, Dabire KR, et al. Physiology and development of the M and S molecular forms of Anopheles gambiae in Burkina Faso (West Africa). Medical and Veterinary Entomology. 2012;26: 447–454. doi: 10.1111/j.1365-2915.2012.01018.x [DOI] [PubMed] [Google Scholar]
  • 38.Detinova TS. Méthodes à appliquer pour classer par groupes d’âge les diptères présentant une importance médicale. Organisation Mondiale de la Santé. Suisse; 1963. [Google Scholar]
  • 39.Polson C, Sarkar P, Incledon B, Raguvaran V, Grant R. Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;785: 263–275. doi: 10.1016/s1570-0232(02)00914-5 [DOI] [PubMed] [Google Scholar]
  • 40.Wohde M, Blanckenhorn WU, Floate KD, Lahr J, Lumaret J-P, Römbke J, et al. Analysis and dissipation of the antiparasitic agent ivermectin in cattle dung under different field conditions. Environ Toxicol Chem. 2016;35: 1924–1933. doi: 10.1002/etc.3462 [DOI] [PubMed] [Google Scholar]
  • 41.R-Development-core-team. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2019.
  • 42.Brien JO, Brooks M. Generalized Linear Mixed Models using Template Model Buider. 2021. [Google Scholar]
  • 43.Crawley M. The R book. Crawley M, editor. Journal of the American Statistical Association. UK: Imperial College London at Silwood Park, UK; 2007. [Google Scholar]
  • 44.Russell VL, Buerkner P, Herve M, Love J, Miguez F, Riebl H, et al. Estimated Marginal Means, aka Least-Squares Means. R topics documented. 2022;34: 216–221. doi: 10.1080/00031305.1980.10483031>.License. [DOI] [Google Scholar]
  • 45.Carnevale P, Manguin S. Review of Issues on Residual Malaria Transmission. J Infect Dis. 2021;223: S61–S80. doi: 10.1093/infdis/jiab084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Takken W, Verhulst NO. Host Preferences of Blood-Feeding Mosquitoes. Annu Rev Entomol. 2013;58: 433–453. doi: 10.1146/annurev-ento-120811-153618 [DOI] [PubMed] [Google Scholar]
  • 47.Alvinerie M, Escudero E, Sutra JF, Eeckhoutte C, Galtier P. The pharmacokinetics of moxidectin after oral and subcutaneous administration to sheep. Veterinary Research. 1998;29: 113–118. [PubMed] [Google Scholar]
  • 48.Ouedraogo A, Bastiaens G, Tiono A, Guelbeogo W, Kobylinski K, Ouedraogo A, et al. Efficacy and Safety of the Mosquitocidal Drug Ivermectin to Prevent Malaria Transmission After Treatment: A Double-Blind, Randomized, Clinical Trial. Clinical Infectious Diseases. 2015;60: 357–65. doi: 10.1093/cid/ciu797 [DOI] [PubMed] [Google Scholar]
  • 49.Kobylinski KC, Tipthara P, Wamaket N, Chainarin S, Kullasakboonsri R, Sriwichai P, et al. Ivermectin metabolites reduce Anopheles survival. Sci Rep. 2023;13: 8131. doi: 10.1038/s41598-023-34719-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Takken W, Verhulst NO. Host Preferences of Blood-Feeding Mosquitoes. Annual Review of Entomology. 2013. doi: 10.1146/annurev-ento-120811-153618 [DOI] [PubMed] [Google Scholar]
  • 51.Tesh RB, Guzman H. Mortality and infertility in adult mosquitoes after the ingestion of blood containing ivermectin. Am J Trop Med Hyg. 1990;43: 229–233 (90–168). doi: 10.4269/ajtmh.1990.43.229 [DOI] [PubMed] [Google Scholar]
  • 52.Kaur M, Graham JP, Eisenberg JNS. Livestock Ownership among Rural Households and Child Morbidity and Mortality: An Analysis of Demographic Health Survey Data from 30 Sub-Saharan African Countries (2005–2015). Am J Trop Med Hyg. 2017;96: 741–748. doi: 10.4269/ajtmh.16-0664 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Slater HC, Walker PGT, Bousema T, Okell LC, Ghani AC. The Potential Impact of Adding Ivermectin to a Mass Treatment Intervention to Reduce Malaria Transmission: A Modelling Study. The Journal of Infectious Diseases. 2014;210: 1972–1980. doi: 10.1093/infdis/jiu351 [DOI] [PubMed] [Google Scholar]
  • 54.Roadmappers Ivermectin. A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool. Am J Trop Med Hyg. 2020;102: 3–24. doi: 10.4269/ajtmh.19-0620 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Heinrich AP, Pooda SH, Porciani A, Zéla L, Schinzel A, Moiroux N, et al. An ecotoxicological view on malaria vector control with ivermectin-treated cattle. Nat Sustain. 2024;7: 724–736. doi: 10.1038/s41893-024-01332-8 [DOI] [Google Scholar]
  • 56.FAO/WHO. Ivermectin: residue monograph. 2016. p. 36. Available: https://openknowledge.fao.org/server/api/core/bitstreams/9432e045-1efe-4476-bfac-563a2847eb7f/content. [Google Scholar]
  • 57.Van Wyk JA. Refugia-overlooked as perhaps the most potent factor concerning the development of anthelmintic resistance. Onderstepoort Journal of Veterinary Research. 2001;68: 55–67. [PubMed] [Google Scholar]
  • 58.Liebig M, Floeter C, Hahn T, Koch W, Wenzel A, Römbke J. Risk Mitigation Measures: An Important Aspect of the Environmental Risk Assessment of Pharmaceuticals. Toxics. 2014;2: 35–49. 10.3390/toxics2010035. [DOI] [Google Scholar]
  • 59.Sagna AB, Zéla L, Ouedraogo COW, Pooda SH, Porciani A, Furnival-Adams J, et al. Ivermectin as a novel malaria control tool: Getting ahead of the resistance curse. Acta Tropica. 2023;245. doi: 10.1016/j.actatropica.2023.106973 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Pedro L Oliveira

3 Jan 2024

PONE-D-23-39281Impact of blood meals taken on ivermectin-treated livestock on survival and fecundity of the malaria vector Anopheles coluzzii under laboratory conditionsPLOS ONE

Dear Dr. Pooda,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Both reviewers did a detailed analysis with several suggestions that will help to improve your manuscript. Please give special attention to the questions on the colony's insecticide resistance status and the lack of correlation between ivermectin plasma concentrations and mortality.

Please submit your revised manuscript by Feb 17 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Pedro L. Oliveira

Academic Editor

PLOS ONE

Journal requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. In your Methods section, please provide additional information regarding the permits you obtained for the work. Please ensure you have included the full name of the authority that approved the field site access and, if no permits were required, a brief statement explaining why.

3. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service. 

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscript

A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

A clean copy of the edited manuscript (uploaded as the new *manuscript* file)".

4. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Pooda and Colls investigated the effects of ivermectin treatments as an ectocide in three livestock species (Sheep, goats and pigs) on the survival and reproduction of the malaria vector Anopheles coluzzii. Different domestic animal species have been used since the pharmacokinetics of Ivermectin may vary between vertebrate hosts. This strategy could be used to complement current control tools such as LLINs and IRS to target exophagic, exophilic and zoophagic vectors. The injectable veterinary ivermectin formulation at the species-specific doses caused a significant decrease in mosquito survival for up to 7 days after injection. The number of gravid females Anopheles that survived after feeding on treated animals was also reduced, as well as the number of mature eggs in the ovaries. However, due to the short-term efficacy of single-dose treatments, repeated treatments and potentially increased dosages would be required to span the transmission season.

The methodology seems to be appropriate, and the results obtained support the conclusions realised by the authors. However, some issues and concerns should be addressed.

1. The authors considered the proportion of females carrying eggs (gravidity rate) and the number of mature eggs in the ovaries as proxies of mosquito fecundity. It is not the optimal way to assess the effect of a drug on reproductive fitness. The presence of a drug may delay ovaries and egg development without affecting the final reproductive output. A better and more direct way to assess reproductive fitness would be to allow the treated females to complete the reproductive cycle, lay the eggs, and count the number of eggs laid by each female and their hatching rate. The final number of F1 per female is the better way to quantify the effect of a drug on reproductive fitness.

2. Which is the insecticide resistance status of the An coluzzii colony used? Please add this information, if known.

3. ¨Lines 235-236: ¨The rate of blood-fed mosquitoes was, respectively, 71.52 (±4.88) %, 71.94 (±3.15) % and 57.46 233 (±2.55) % on sheep, goat and pig at the first blood meal (Figure 1)¨.

Were these values calculated using both control and Ivermectin-treated animals? Please clarify this issue.

4. Figure 1: Change DT for TD in the X-axis information. What’s the meaning of ten in the X-axis legend? This figure is difficult to interpret and contains some mistakes. I guess the pink columns are the insects fed on control animals, blue are mosquitoes fed on therapeutical dose-treated animals (TD), while green and violet colours are 2TD and 3DT in mosquitoes fed on pigs. Please clarify this and accommodate the order of columns in panel C according to panels A and B. Add ¨3TD¨ at figure legend.

5. Line 255-256: ¨The doubled and tripled therapeutic doses used to treat pigs induced as well a significant decrease in mosquito mortality rates¨

Should be ¨ a significant increase¨

6. Figure 2: There seems not to be differences in survival in IVM-treated and control goats on day 2 DPI. Please check it. Besides, the mortality in pigs is higher for TD than for 2TD on day 2 DPI. Please also check this issue. Add the time units in the X-axis (days?)

7. Line 282-283: From day 14 post-treatment and onwards, there was no significant difference between groups whatever the host species considered (Figure 1).

Should be ¨ Figure 2¨

8. Figures 3 and 4: Please, add asterisks to the statically significant differences between control and IVM-treated animals.

9. There is no correlation in the mean plasma concentrations of ivermectin (ng/mL) in the treated- sheep, goats and pigs (table II) with the mortality observed in Figure 2 and the number of eggs in Figure 4. Can the authors explain this? For example, in pigs, only the 3TD caused increased mortality on day 14 DPI, but the concentration is as high as 2TD, which did not increase mortality on that day. Besides, 2TD on pigs doubles the concentration in goats at 2 DPI and in sheep at 7 DPI, and both increased mosquitoes mortality. A deeper discussion about the lack of correlation in plasma IVM concentrations and the phenotypes observed associated with reduced survival and reproductive fitness is needed. The lack of correlation makes the interpretation of the results very difficult.

Reviewer #2: PONE-D- 23-39281

Impact of blood meals taken on ivermectin-treated livestock on survival and fecundity of the malaria vector Anopheles coluzzii under laboratory conditions

This review is by Carlos Chaccour from ISGlobal, Barcelona Institute for Global Health. I have a personal open peer-review policy as the current single-blinded system is riddled with vices.

This manuscript reports the results of an experiment conducted in Burkina Faso in which pigs, sheep and goats were treated with different doses of ivermectin and then An. coluzii mosquitoes were fed on them at different times after treatment. The authors also collected some PK data. The results are discussed on the context of a potential One Health approach to malaria control.

Albeit some minor mistakes, the manuscript is well written. The methods are appropriate for the objectives and the conclusion is supported by the result. I provide here comments for the author`s consideration.

Introduction

Consider mentioning early exit as another mosquito behavior contributing to residual transmission. This can be induced by the repellent properties of indoor insecticides or occur even in their absence.

There is no mention of two key concepts: zooprophylaxis vs zoopotentiation.

Methods

Please mention the colony`s insecticide resistant status. This is important given the potential cross-metabolic resistance with pyrethroids as they share the same CYP as ivermectin.

Please mention the calculated adipose vs lean weight of the animals.

How was the random allocation of mosquito cups done?

Were cups rotated in the insectary?

Figure 2 is pixelated, making reading it difficult. Additionally, the X axis seems compressed, giving the illusion that the curves are smooth rather than the usual K-M step by step drop. I recommend providing a higher quality image and perhaps even separating it in three different figures to ensure sufficient size. Consider also adding guiding marks to the reader such as the median survival in the control group.

Results

The increased gravity found at 28 DAI in goats does not seem to be statistically significant as the CI overlap in figure 3. If that is the case, I recommend, stating it in the text.

The same for the decrease in fecundity reported at day 28 in sheep, or 7 DAI in goats, although in these cases p-values are provided in the text, it is worth it to double check the figure given that CI-overlap.

Table II. The metric should be median and range given the samples come from only two animals.

Can the authors use the PK data to estimate the 7-day LC50?

What hypotheses do the authors have about the disparity between the ivermectin concentrations and the mosquito mortality seen in pigs?

There is no mention of toxicity in the livestock. Did the authors monitor for toxicity in pigs given three-fold doses?

Discussion

Please comment in the expected relative densities of each livestock species in the field. Are goats more common than cattle? What order of livestock treatment would you recommend? Cattle > Pigs > Goat > Sheep? Or other?

There is no mention about the milk or slaughter withdrawal periods and how this may affect deployment of the proposed strategy.

Please consider mentioning the potential impact of intense treatment schemes or long-lasting formulations on intestinal parasites resistance. What role could refugia play?

There is also no mention about the potential long-term theoretical risk of selectin a more anthropophilic mosquito population.

Minor

Lines 482. Passed away. Not “are passed away”. Also Rest in peace not “rested in peace”

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Marcos Sterkel

Reviewer #2: Yes: Carlos Chaccour

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-23-39281.docx

pone.0308293.s007.docx (18.5KB, docx)
PLoS One. 2024 Aug 15;19(8):e0308293. doi: 10.1371/journal.pone.0308293.r002

Author response to Decision Letter 0


1 Jul 2024

PONE-D- 23-39281

Impact of blood meals taken on ivermectin-treated livestock on survival and fecundity of the malaria vector Anopheles coluzzii under laboratory conditions

Responses to Editor:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

Response: These requesting has been taken account.

2. In your Methods section, please provide additional information regarding the permits you obtained for the work. Please ensure you have included the full name of the authority that approved the field site access and, if no permits were required, a brief statement explaining why.

Response: Information about the permits obtained for the work has been added to the Materials and Methods’ section of the revised manuscript (lines 118–121).

3. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Response: These requesting has been taken account. The co-authors edited the manuscript.

4. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

Response: This has been corrected in the revised manuscript (lines 492-495).

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

Response: The ethics statement has been moved to the Materials and Methods section as suggested (lines 118–121).

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Response: The changes have been made in the Supporting Caption on lines 476-481.

Response to the Reviewer #1:

Pooda and Colls investigated the effects of ivermectin treatments as an ectocide in three livestock species (Sheep, goats and pigs) on the survival and reproduction of the malaria vector Anopheles coluzzii. Different domestic animal species have been used since the pharmacokinetics of Ivermectin may vary between vertebrate hosts. This strategy could be used to complement current control tools such as LLINs and IRS to target exophagic, exophilic and zoophagic vectors. The injectable veterinary ivermectin formulation at the species-specific doses caused a significant decrease in mosquito survival for up to 7 days after injection. The number of gravid females Anopheles that survived after feeding on treated animals was also reduced, as well as the number of mature eggs in the ovaries. However, due to the short-term efficacy of single-dose treatments, repeated treatments and potentially increased dosages would be required to span the transmission season.

The methodology seems to be appropriate, and the results obtained support the conclusions realised by the authors. However, some issues and concerns should be addressed.

Response: We thank sincerely Dr Marcos Sterkel for the reading and analyzing our paper. We appreciated greatly your observations made about this work.

1.The authors considered the proportion of females carrying eggs (gravidity rate) and the number of mature eggs in the ovaries as proxies of mosquito fecundity. It is not the optimal way to assess the effect of a drug on reproductive fitness. The presence of a drug may delay ovaries and egg development without affecting the final reproductive output. A better and more direct way to assess reproductive fitness would be to allow the treated females to complete the reproductive cycle, lay the eggs, and count the number of eggs laid by each female and their hatching rate. The final number of F1 per female is the better way to quantify the effect of a drug on reproductive fitness.

Response: We agree that using only the number of mosquito females carrying eggs and the number of mature eggs per female gives only part of the answer on the impact of ivermectin on the overall reproductive fitness of Anopheles coluzzii. We are however confident that we are not observing a delay in ovaries and egg development and that the number of eggs we counted by gravid female represents the final output in terms of the maximum number of eggs that a female could carry, since we let the female to develop eggs for 4 days post blood-meal, and since during dissection, all the eggs observed and counted under a binocular were mature (Christopher stage 5). Moreover, no remaining, undigested blood, has been observed. We are however aware about the fact that these counts (% gravids and number of eggs per female) represent only a “potential” and that the actual number of laid eggs and, moreover, the number of larvae that develop from these eggs illustrate better the actual reproductive fitness. Although other authors used as well the number of eggs counted through dissection as a fecundity index (Mekuriaw et al. Malar J (2019) 18:357 https://doi.org/10.1186/s12936-019-2988-3), we took into consideration the reviewer’s remark and modified several sentences accordingly throughout the text, including the manuscript title (fecundity was replaced by eggs production). We directly addressed this issue in the materials and methods section, lines 207-210, by acknowledging the fact that we present a proxy of the fecundity expressing a potential only.

“The proportion of females carrying developed eggs (gravidity rate) and the number of mature eggs (i.e., those that reached Christopher stage V of ovarian development) [39] are proxies representing important parameters of the mosquitoes reproductive potential.”

2.Which is the insecticide resistance status of the An. coluzzii colony used? Please add this information, if known.

Response: The colony we used during our experiments in 2017 and 2018 was the same as in the study from Pooda et al. 2015. Like stated in this article, the colony was repeatedly replenished with wild mosquitoes from the village of Bama, where founder individuals were collected as well and where the mutated kdr allele prevalence is very high. We therefore assume that we also dealt with mosquito batches displaying the same proportion of pyrethroid resistant mosquitoes than previously reported, which was 30-40%. This information is now added in the manuscript lines 123-134.

“A colony of one of the major vectors of Plasmodium, An. coluzzii, was used in this study. The colony was established in year 2008 from 200 wild blood-fed females captured inside houses using a mouth aspirator at the Kou Valley (11 ° 23′14 ″ N, 4 ° 24′42 ″ W) near Bobo-Dioulasso, South-Western Burkina Faso, was used in this study. It is the same than the one used for the study by Pooda et al. (2015), with a proportion of 30-40% mosquitoes carrying the kdr-resistant allele conferring resistance to pyrethroids. It was repeatedly replenished with F1 from wild-caught mosquito females collected in the same area. This Anopheles species is one of the major vectors of Plasmodium parasites in Burkina Faso [33]. The species composition of the colony, its resistance to insecticides status, and potential contamination by other species or strains was routinely checked using PCR as previously described [34] »

3. Lines 235-236: The rate of blood-fed mosquitoes was, respectively, 71.52 (±4.88) %, 71.94 (±3.15) % and 57.46 233 (±2.55) % on sheep, goat and pig at the first blood meal (Figure 1).

Were these values calculated using both control and Ivermectin-treated animals? Please clarify this issue.

Response: The values presented here were calculated with the overall data considering mosquitoes fed on control and treated animals. This is because there were no significant differences between treatments. Details of the number of mosquitoes fully engorged for each group of animals and at all considered time points are given in the Supplementary Table S1. The reviewer’s comment has been taken into account and the reported sentence has been completed as follows, lines 248-255:

“There was no effect of the treatment of ivermectin on the rate of mosquitoes blood-fed on sheep (χ21=0.0867, P = 0.77), goats (χ21=0.1071, P = 0.74) and on pigs (χ23=2.5833, P = 0.46), with no significant difference between mosquitoes fed on corresponding treated and control animals (S1 Table). All samples taken together, the rate of blood-fed mosquitoes during the first blood meal was, respectively, 71.52 (±4.88) %, 71.94 (±3.15) % and 57.46 (±2.55) % on sheep, goat and pig at the first blood meal (Figure 1), and was, for the second blood meal, 59.57 (±4.55) %, 58.26 (±5.53) %, and 69.46 (±2.74) %. The sample size for each mosquito group is given in the supporting S1 Table”.

4. Figure 1: Change DT for TD in the X-axis information.

Response: This has been done, see the Figure 1

What’s the meaning of ten in the X-axis legend? This figure is difficult to interpret and contains some mistakes. I guess the pink columns are the insects fed on control animals, blue are mosquitoes fed on therapeutical dose-treated animals (TD), while green and violet colours are 2TD and 3DT in mosquitoes fed on pigs. Please clarify this and accommodate the order of columns in panel C according to panels A and B. Add ¨3TD¨ at figure legend.

Response: We thank the reviewer for his remarks to improving the quality of our figure. However, we are quite puzzled because they do not seem to fit if we consider the Figure 1 that we believe we submitted together with our manuscript (see below). We are confused and we very much apologize because the mistake must come from our side with a preliminary instead of final Figure 1 submitted. We hope that the reviewer will find the actual Figure 1 below being suitable for illustrating our results about the proportion of Anopheles females that fed on hosts of different species treated with different ivermectin doses. As for answering to the question “What’s the meaning of ten in the X-axis legend?”, there is no more “10” in the X-axis legend.

Response: The corrected figure 1 is uploaded.

5. Line 255-256: The doubled and tripled therapeutic doses used to treat pigs induced as well a significant decrease in mosquito mortality rates

Should be ¨ a significant increase

Response: This has been corrected in the manuscript. This reads now at lines 298 - 306.

6. A. Figure 2: There seems not to be differences in survival in IVM-treated and control goats on day 2 DPI. Please check it.

Response: Thank you for your observations. For this specific experimental point at 2DAI, the statistical analyses showed a significant decrease in Anopheles survival between IVM-treated and control goats (HR = 1.46, IC [1.09 – 1.95]; P= 0.01). The effect is not graphically obvious due to the duration of the follow up per se (until all mosquitoes died) but also, an unexpected low survival rate in the control arm occurred at this DAI. However, this result is statistically supported (lines: 281-286). The median survival at 2 DAI was 9 days for the control mosquitoes (8, 8, and 9 days for the three goats, respectively) and 7 days for mosquitoes that fed on treated goats (7, 6, and 7 days for the three IVM-treated goats, respectively).

6. B. Besides, the mortality in pigs is higher for TD than for 2TD on day 2 DPI. Please also check this issue.

Response: To better visualize mortality data we obtained when exposing mosquitoes to control and treated pigs 2 days after injection of ivermectin, we plotted below the survival curves for this DAI and for the different treatments. We can notice the variability of the toxic effect generated by blood feeding on the pigs P3 and P6 from the 2TD, and also the TD treatments. Such variability is directly linkable to the variability observed in ivermectin concentration values (see table 2 below).

Figure 2. Survival curves for mosquitoes from the same lot fed on control (P1 and P8) and treated pigs 2 DAI after treatments. Ivermectin treatments were injected at the therapeutic dose (TD, P2 and P7), the double (2TD, P3 and P6) and the triple (3TD, P4 and P5) therapeutic dose.

The pharmacokinetic/pharmacodynamic of ivermectin varies greatly among species, and, considering the same species, it varies also greatly among individuals, depending mostly on the treated animal’s weight, physiology (in particular fat tissue percentage) and the injection act per se, which is subject to variations (in precision and speed) from an animal to another because animals’ tremors, movements, and because human variability from an injection to another as well.

Pharmacokinetics variability among the 2 animals of the 2TD treatment (for the reasons mentioned above) might be at the origin of the results observed between TD and 2TD that the reviewer mentioned, with one from both displaying an ivermectin concentration that is as low as the one observed at 14 DAI for the TD treatment (6-7 ng/ml) where variability between animals is low and where this concentration is not associated with significant mortality in mosquito batches fed on these treated pigs. For the same species, inter-individual PK variability is highlighted in table 2 and was already discussed in our manuscript, lines 399-401. This is now mentioned in the results section as well, lines 355 – 356: “For pigs in particular, a great inter-individual host variability in ivermectin plasma concentration can be noticed.” This issue would be solved using more pigs per treatment. However, already published data considered 2 pigs only as well in their protocol (Pasay et al. Parasites Vectors (2019) 12:124 https://doi.org/10.1186/s13071-019-3392-0).

6.C. Add the time units in the X-axis (days?)

“Days after blood meal” as the time units have been added to the Figure as requested.

7. Line 282-283: From day 14 post-treatment and onwards, there was no significant difference between groups whatever the host species considered (Figure 1).

Should be ¨ Figure 2¨

Response: Thank you very much. This has been corrected in the manuscript at now lines 296-297.

8. Figures 3 and 4: Please, add asterisks to the statically significant differences between control and IVM-treated animals.

Response: Asterisks have been added to the statically significant differences between control and IVM-treated animals as suggested.

9.A. There is no correlation in the mean plasma concentrations of ivermectin (ng/mL) in the treated- sheep, goats and pigs (table II) with the mortality observed in Figure 2 and the number of eggs in Figure 4. Can the authors explain this?

9.B. For example, in pigs, only the 3TD caused increased mortality on day 14 DPI, but the concentration is as high as 2TD, which did not increase mortality on that day.

9.C. Besides, 2TD on pigs doubles the concentration in goats at 2 DPI and in sheep at 7 DPI, and both increased mosquitoes’ mortality. A deeper discussion about the lack of correlation in plasma IVM concentrations and the phenotypes observed associated with reduced survival and reproductive fitness is needed. The lack of correlation makes the interpretation of the results very difficult.

9.A and 9.C. Inter-species variability in PK/PD:

Response: There is evident great discrepancy in plasma levels between species, and not only because the administered doses are different (see Table 2). This has been already reported (Alvinerie et al., 1998; Veterinary Research, 1998, 29: 113-18) and is highly explaine

Attachment

Submitted filename: Response to Reviewers.pdf

pone.0308293.s008.pdf (742KB, pdf)

Decision Letter 1

Pedro L Oliveira

22 Jul 2024

Impact of blood meals taken on ivermectin-treated livestock on survival and egg production of the malaria vector Anopheles coluzzii under laboratory conditions

PONE-D-23-39281R1

Dear Dr. Pooda,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Pedro L. Oliveira

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript has been significantly improved from its initial version. All of my comments and concerns have been resolved in this new version. I appreciate the authors' efforts in strengthening the discussion about the correlation between plasma levels and the observed phenotypes. After a second revision, I found no further issues to be addressed.

Reviewer #2: The authors have submitted a detailed "answer to reviewers" section. All my comments have been appropriately addressed. All changes in the manuscript are appropriately tracked

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Marcos Sterkel

Reviewer #2: Yes: Carlos Chaccour

**********

Acceptance letter

Pedro L Oliveira

6 Aug 2024

PONE-D-23-39281R1

PLOS ONE

Dear Dr. Pooda,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Pedro L. Oliveira

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Number of exposed, blood-fed and dissected female Anopheles according to the hosts species, the treatment and the time elapsed since the injection (DAI).

    (PDF)

    pone.0308293.s001.pdf (165KB, pdf)
    S1 File. Preliminary study: Efficacy of blood meal taken on treated pigs with therapeutic dose of ivermectin on the survival of Anopheles coluzzii.

    (PDF)

    pone.0308293.s002.pdf (197.7KB, pdf)
    S2 File. Gravidity rate and fecundity in females Anopheles coluzzii fed on pig.

    (PDF)

    pone.0308293.s003.pdf (271.9KB, pdf)
    S3 File. Data set on the bloodmeal rate of Anopheles coluzzii.

    (TXT)

    pone.0308293.s004.txt (19.7KB, txt)
    S4 File. Data set on the survival of Anopheles coluzzii.

    (TXT)

    pone.0308293.s005.txt (314.7KB, txt)
    S5 File. Data set on the gravidity status and the number of eggs developed in Anopheles coluzzii.

    (TXT)

    pone.0308293.s006.txt (131.4KB, txt)
    Attachment

    Submitted filename: PONE-D-23-39281.docx

    pone.0308293.s007.docx (18.5KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.pdf

    pone.0308293.s008.pdf (742KB, pdf)

    Data Availability Statement

    All data supporting these results are available in the Supporting Information S3 File to S5 File.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES